LOS ANGELES, May 8, 2019 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today highlighted
that it has been issued a patent from the U.S. Patent and Trademark
Office (USPTO) covering the use of aldoxorubicin intravenously,
intra-arterially or intramuscularly for the treatment of brain
cancer, which patent was exclusively licensed by CytRx to NantCell,
Inc. in July 2017. The new patent issued on May 7, 2019 as U.S. Patent No. 10,278,981, is
titled "Cytotoxic Agents for The Treatment of Cancer."
"We are continually impressed with the progress that our partner
and licensee NantCell has made with advancing aldoxorubicin in high
unmet need oncology indications," said Eric
Curtis, CytRx's President and Chief Operating Officer. "As
NantCell continues to produce promising combination data in disease
areas such as triple negative breast cancer, head and neck squamous
cell carcinoma and recurrent metastatic pancreatic cancer, we are
pleased to see that they are committed to exploring the drug's
utility in other disease areas such as colorectal cancer, and now
potentially brain cancer, where we believe may transform the
treatment paradigm for patients. We look forward to seeing
NantCell's further progress with the growing list of aldoxorubicin
applications."
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical company
with expertise in discovering and developing new therapeutics to
treat patients with cancer. CytRx's most advanced drug conjugate,
aldoxorubicin, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc. In addition, CytRx's other drug candidate, arimoclomol,
has been out-licensed to Orphazyme A/S (Nasdaq Copenhagen exchange:
ORPHA). Orphazyme is testing arimoclomol in four indications
including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease
Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis
(sIBM). CytRx Corporation's website is www.cytrx.com.
About Centurion BioPharma Corporation
CytRx's wholly owned subsidiary, Centurion BioPharma
Corporation, is focused on the development of personalized medicine
that is designed to transform solid tumor treatment. This
transformational strategy combines a portfolio of novel,
anti-cancer drug candidates that employ LADR™ (Linker Activated
Drug Release) technology, a discovery engine designed to leverage
Centurion's expertise in albumin biology and linker technology for
the development of a new class of breakthrough anti-cancer
therapies with a unique albumin companion diagnostic (ACDx) that
can help identify patients who are most likely to benefit from
treatment with the LADR™-derived therapies. A critical element of
the LADR™ platform is its ability to bind anti-cancer molecules to
circulating albumin, the most ubiquitous protein in human blood
plasma, and then to release the highly potent cytotoxic payload at
the tumor site. This technology allows for the delivery of higher
doses of drug directly to the tumor, while avoiding much of the
off-target toxicity observed with the parent molecules. Centurion
BioPharma Corporation's website is www.centurionbiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its LADR™
technology platform; our ability to attract potential licensees;
and other risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report.
All forward-looking statements are based upon information
available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. References and links to websites
have been provided as a convenience, and the information contained
on such websites is not incorporated by reference into this press
release.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-patent-issued-for-use-of-aldoxorubicin-in-the-treatment-of-brain-cancer-300846068.html
SOURCE CytRx Corporation
